治疗慢性鼻炎的系统性皮质类固醇- 一个系统性审查
Sarah Tamene1, Kim Dalhoff2, Peter Schwarz3
1Department of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
European clinical respiratory journal
|August 9, 2023
概括
注射性皮质类固醇可能为慢性鼻炎 (CRS) 提供更持久的缓解,副作用比口服皮质类固醇 (OCS) 少,尽管需要更多的研究.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性鼻炎 (CRS) 治疗通常会在一线治疗中失败.
- 系统性皮质类固醇,包括口服皮质类固醇 (OCS) 和注射性皮质类固醇,在初始治疗失败时使用.
- 国际CRS指南不规定注射性皮质类固醇的使用,尽管它们被专家普遍使用.
研究的目的:
- 在CRS治疗中,系统地审查注射与口服皮质类固醇的作用和副作用.
- 为了澄清CRS的不同皮质类固醇注射途径的优缺点.
主要方法:
- 根据PRISMA指南进行了系统审查.
- 包括报告CRS中注射和口服皮质类固醇的影响和/或副作用的研究.
- 总共分析了48项研究.
主要成果:
- 只有五项研究报告了注射性皮质类固醇,其中五项研究了副作用.
- 口服皮质类固醇在一些研究中显示了术后的好处,但结果是混合的.
- 十九篇文章表明,OCS可以改善症状;两项研究表明,注射皮质类固醇的效果更持久.
- 与OCS相比,注射皮质类固醇在有限的研究中发现的不良副作用和上腺抑制较少.
结论:
- 对CRS的口服皮质类固醇和注射皮质类固醇进行比较的证据很少.
- 注射性皮质类固醇似乎提供了比OCS更持久的效果和可能更少的副作用.
- 需要进一步的随机对照试验 (RCT) 来直接比较CRS治疗中的OCS和注射皮质类固醇.
更多相关视频
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
299
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
299
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Drugs Used in Upper Respiratory Disorders: Overview
290
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
290
Drugs Used in Lower Respiratory Disorders: Overview
489
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
489
COPD: Management Using Bronchodilators and Corticosteroids
244
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
244
Cystic Fibrosis: Management
194
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
194


